60 likes | 323 Vues
RnRMarketResearch.com adds “Hereditary Angioedema (HAE) - Pipeline Review, H1 2015” to its Store. The Report Provides the Latest News and Market Review along with the Industry Updates of the Hereditary Angioedema (HAE)'s therapeutic pipeline.
E N D
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 By RnRMarketResearch Browse more reports on Pharmaceuticals are available at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . (This is a premium report price at US$2000 for a single user PDF license) ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 Global Markets Direct's, ‘Hereditary Angioedema (HAE) - Pipeline Review, H1 2015', provides an overview of the Hereditary Angioedema (HAE)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 • Scope: • Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MoA, route of administration and molecule type. • A detailed assessment of monotherapy and combination therapy pipeline projects. • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. • A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 • Reasons to buy: • Develop strategic initiatives by understanding the focus areas of leading companies. • Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. • Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441